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Introduction
Psoriasis is a chronic, inflammatory, immune-
mediated  skin  disease  characterized  by  increased 
epidermal proliferation and differentiation, and ac-
celerated  angiogenesis  with  dilated  blood  vessels 
and inflammation in the skin [1]. The prevalence of 
psoriasis is the same in both sexes, and in all socio-
economic groups in the society [2]. Epidemiologic 
and immunogenetic studies have indicated that pre-
disposition  for  psoriasis  is  hereditary.  Belić  et  al. 
have shown the correlation among hereditary com-
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Summary
Introduction. Psoriasis is a chronic, inflammatory, immune-me-
diated skin disease. In addition to standard therapeutic modalities 
(antibiotics, cytostatics, phototherapy, photochemotherapy and re-
tinoids), nonstandard methods can be used in the treatment of 
psoriasis. This includes balneotherapy which is most commonly 
used in combination with therapeutic resources. The aim of this 
research was to determine the length of remission of psoriasis in 
patients treated with standard therapeutic modalities, balneothe-
rapy, and combined treatment (standard therapeutic modalities 
and balneotherapy). Material and Methods. The study analyzed 
60 adult patients, of both sexes, with different clinical forms of 
psoriasis, who were divided into three groups according to the 
applied therapeutic modalities: the first group (treated with stan-
dard therapeutic modalities), the second group (treated with bal-
neotherapy) and the third group (treated with combined therapy-
standard methods therapy and balneotherapy). The Psoriasis Area 
and Severity Index was determined in first, third and sixth week 
of treatment for all patients. The following laboratory analysis 
were performed and monitored: C reactive protein, iron with total 
iron binding capacity, unsaturated iron binding capacity and ferri-
tin, uric acid, rheumatoid factors and antibodies to streptolysin O 
in the first and sixth week of treatment. Results. The average len-
gth of remission in patients treated with standard therapeutic mo-
dalities and in those treated with balneotherapy was 1.77 ± 0.951 
months and 1.79 ± 0.918 months, respectively.  There was a stati-
stically significant difference in the duration of remission between 
the patients treated with combination therapy and patients treated 
with standard therapeutic modalities (p=0.019) and balneotherapy 
(p=0.032). Conclusion. The best results have been achieved when 
the combination therapy was administered.
Key words: Psoriasis; Drug Therapy; Balneology; Combined 
Modality Therapy; Remission Induction; Body Surface Area; 
Severity of Illness Index; Diagnostic Tests, Routine
Sažetak
Uvod. Psorijaza je hronična, inflamatorna, imunoposredova-
na kožna bolest. Pored standardnih terapijskih modaliteta (anti-
biotici, citostatici, fototerapija, fotohemoterapija i retinoidi), u 
terapiji se primenjuju i nestandardne terapijske metode kao bal-
neoterapija, ali najčešće kombinacija više terapijskih sredstava. 
Cilj rada bio je da se utvrdi dužina remisije psorijaze kod paci-
jenata lečenih standardnim terapijskim modalitetima, balneo-
terapijom i kombinovanim lečenjem (standardnim terapijskim   
modalitetima i balneoterapijom). Materijal i metode. Analizi-
rano je 60 odraslih pacijenata oba pola, obolelih od različitih 
kliničkih oblika psorijaze, podeljenih  u tri grupe prema prime-
njenim terapijskim modalitetima: grupa I (lečena standardnim 
terapijskim modalitetima), grupa II (lečena balneoterapijom) i 
grupa III (lečena kombinovanim terapijskim modalitetima − 
standardnim metodama i balneoterapijom). Svim pacijentima 
smo određivali indeks procene težine psorijaze u 1, 3. i 6. nede-
lji lečenja. Pratili smo laboratorijske  analize: C-reaktivni pro-
tein, gvožđe, ukupni kapacitet vezanog gvožđa, kapacitet vezi-
vanja nezasićenog gvožđa, feritin, mokraćnu kiselinu, reuma-
toidne faktore i antitela na streptolizin O u 1. i 6. nedelji lečenja. 
Rezultati.  Prosečna  dužina  remisije  kod  pacijenata  lečenih 
standardnim terapijskim modalitetima iznosi 1,77 ± 0,951 me-
seci,  a  kod  pacijenata  lečenih  balneoterapijom  iznosi  1,79  ± 
0,918 meseci. Kod pacijenata lečenih kombinovanom terapijom, 
period remisije je u proseku trajao 2,47 ± 0,743 meseci. Postoji 
statistički značajna razlika u dužini trajanja remisije između 
pacijenata lečenih kombinovanom terapijom i pacijenta lečenih 
standardnim  terapijskim  modalitetima  (p  =  0,019),  odnosno 
balneoterapijom p = 0,032). Zaključak. Primena kombinovane 
terapije pokazala je najbolje rezultate u lečenju psorijaze.
Ključne reči: Psorijaza; Terapija; Balneologija; Kombinovani 
terapijski modaliteti; Remisija; Površina tela; Indeks procene 
težine bolesti; Rutinski dijagnostički testovi
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ponent, frequency and time of appearance of psoria-
sis [3]. Psoriasis is associated with a certain human 
leukocyte antigen (HLA), and it is believed that the 
immune system plays an important role in the patho-
genesis of psoriasis [4]. Poljački et al. have found as-
sociation between psoriasis and other dermatologi-
cal diseases (lichen planus, alopecia areata and vitil-
igo) [5]. Psoriasis is characterized by clearly defined 
erythematous plaques and/or papules that are cov-
ered by silver-white scaling. According to the degree 
of the skin involvement, psoriasis can be localized 
or generalized, which may turn into erythrodermia 
(involvement of skin greater than 90%) [6-8]. This 
disease  may  be  acute,  subacute,  but  it  is  usually 
chronic. The plaque form of psoriasis is the most 
common form of psoriasis [9]. The diagnosis of pso-
riasis is usually set on the basis of medical history, 
clinical and diagnostic signs (”stearin candles”, ”last 
skins” and ”blood droplets”) [10]. The definitive di-
agnosis is confirmed by pathological examination 
[11].  According  to  the  percentage  of  the  affected 
skin,  which  is  determined  by  Evans  formula  for 
burn, calculating the Psoriasis Area and Severity In-
dex (PASI score), which analyzes the degree of ery-
thema, infiltration and desquamation on the affected 
skin. Reduction in PASI score of 75% is considered 
the ”gold standard” for measuring the response to 
therapy (PASI-75) [12–14]. In patients with psoriasis, 
we can see a variety of laboratory abnormalities, 
such as the increased concentrations of C-reactive 
protein (CRP), leukocytosis with a predominance of 
neutrophils, increased elastase, lactoferrin and α1-
antitrypsin. Neutrophils play a key role in the clini-
cal  development  of  psoriasis.  Monitoring  these 
markers could predict relapse of the disease. In addi-
tion, there is also anemia, thrombocytosis and hype-
ruricemia [15–19]. Patients with psoriasis often have 
negative values of rheumatoid factor. Increased val-
ue of rheumatoid factor appears among elderly pa-
tients with psoriasis and in patients with psoriasis 
with rheumatic comorbidity [20]. Increased levels of 
antibodies to streptolysin O (ASO titre) were found 
in the serum of patients in response to infection with 
hemolytic streptococcus groups A, C or G. Strepto-
coccal  infection  usually  leads  to  eruptive  guttate 
psoriasis, and deterioration of other clinical forms of 
psoriasis. Therefore, it makes sense to introduce an-
tibiotic therapy in such patients [21,22].
Treatment  of  psoriasis  requires  a  multidiscipli-
nary approach. The combination of multiple thera-
peutic agents is another approach to the treatment of 
psoriasis and is convenient because it reduces the cu-
mulative toxic effects of the disease [23]. Standard 
therapeutic modalities include phototherapy (ultravi-
olet B (UVB), combined ultraviolet A (UVA) and 
UVB wave), photochemotherapy (UVA - with sys-
temic photosensitizer - PUVA), combination of retin-
oids and PUVA (Re-PUVA), cytotoxic therapy, retin-
oids, antibiotic and biological therapy [24–27]. Local 
treatment of psoriasis includes local corticosteroid 
therapy,  vitamin  D  analogues,  anthralin  prepara-
tions, tar and topical retinoids, calcineurin inhibitors, 
keratinolytics and emollients [28, 29]. In addition to 
standard  therapeutic  modality  in  the  treatment  of 
psoriasis, we can also use non-therapeutic procedure, 
such as balneotherapy [30–33]. Application of ther-
mal mineral water containing sulfur can have a good 
therapeutic effect on psoriasis and other skin diseas-
es. Thermal water also has anti-inflammatory, kerat-
oplastic and antipruritic effect. It is used as a single 
modality or in combination with other therapeutic 
modalities [34–37].
The aim of this study was to determine the du-
ration of remission of psoriasis in patients treated 
with standard therapeutic modalities, balneothera-
py and combination treatment (standard therapeu-
tic modalities and balneotherapy). It is also neces-
sary to determine whether there is a statistically 
significant difference in the duration of remission 
of psoriasis when compared to the applied treat-
ments of psoriasis.
Material and Methods
This  prospective  study  included  60  adult  pa-
tients, of both sexes, with different clinical forms of 
psoriasis. Graph 1 shows the structure of patients 
by sex and age. The study sample included 60 pa-
tients, 62% men and 38% women. Most of the re-
spondents (25.0%) were older than 60 years of age, 
and 11.7% younger than 29 years of age. The most 
common form of psoriasis in the total number of 
respondents was a generalized form of plaque pso-
riasis, which was diagnosed in 21 cases (35%). Oth-
er forms were less present (Graph 2).
The patients were randomly selected from those 
who had consulted the doctor at the Department of 
Dermatology and Venereal Diseases of the Clinical 
Center  of  Banja  Luka.  All  the  respondents  gave 
their written consent to be included in the study. 
Their data were entered in the questionnaire de-
signed according to the data analyzed in the study. 
The questionnaire contained basic information about 
the patients, their diagnosis, therapeutic modality, 
PASI score in the first, third and sixth week, and 
the value of laboratory tests in the first and sixth 
week.  Psoriasis  was  diagnosed  according  to  the 
clinical parameters and histological analysis of the 
modified skin in all patients. PASI score was deter-
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mined according to the severity of illness and the 
total area of the affected skin. 
The patients were divided into three groups ac-
cording to the applied therapeutic modalities:
The patients at the Department of Skin and Ve-
nereal Diseases, Clinical Center of Banja Luka, 
treated  with  standard  therapeutic  modalities  (26 
patients).  The  standard  therapeutic  modality  in-
volved systemic antibiotic therapy, methotrexate, 
phototherapy  and  photochemotherapy.  Local  ke-
ratinolytic therapy, corticosteroid preparations, di-
tranol and emollients were also applied.
The  patients  with  different  clinical  forms  of 
psoriasis treated with balneotherapy at the Kulaši 
Spa, Republic of Srpska, for three weeks (19 pa-
tients). Water of Kulaši Spa has characteristics of 
healing thermal mineral water, its temperature be-
ing 30.6 degrees Celsius. Water is sterile, highly 
alkaline (pH 11.75) with low mineralization (168 
mg/l). The spa water was used twice a day in the 
form of baths, hot tubs and swimming in the pool 
for  half  an  hour.  The  patients  with  less  severe 
forms of psoriasis used bath tubs, while the pa-
tients with moderate and severe forms of psoriasis 
swam in the pool twice a day for half an hour. Af-
ter the end of treatment, the neutral local therapy 
(Galsanae cream) was prescribed.
The patients with psoriasis who were treated 
with  standard  therapeutic  modalities  combined 
with balneotherapy (15 patients). After hospitali-
zation or outpatient treatment at the Department 
of Skin and Venereal Diseases, Clinical Center of 
Banja Luka, the patients were sent to the Kulaši 
Spa, for a period of 21 days. In cooperation with 
the dermatovenerologist, the spa treatment proto-
col was determined according to the severity of 
the clinical picture measured on PASI score. 
Remission  was  followed  over  the  period  of 
three months. The clinical examination and PASI 
scores were measured in the first, third and sixth 
week of treatment to determine the period of re-
mission. At the beginning and at the end of the 
study, all patients underwent the following labora-
tory tests: ASTO, Rheumatoid factor (Rf), CRP, 
uric acid, iron with ferritin (determined only at the 
end of the treatment) and total iron binding capac-
ity  (TIBC),  unsaturated  iron  binding  capacity 
(UIBC).
The statistical analysis of the results used de-
scriptive  and  analytical  statistics.  For  statistical 
analysis of data, the Statistical Package for the So-
cial Sciences (SPSS) (version 17) was used. 
Results
The average values of PASI score were deter-
mined in the first, third and sixth week of the treat-
ment (Table 1). Fisher’s Exact Test showed a statis-
tically significant difference (p=0.049) in the mean 
valu- es of PASI score in the first week of treatment 
among different groups. In the first week, the pa-
tients treated with standard therapeutic modalities 
had PASI score values significantly higher than in 
the group of patients treated with balneotherapy, 
but in comparison with the group of patients treated 
with combined therapy, there were no statistically 
significant differences in the values of PASI scores. 
During the second measurement (the third week), 
the mean PASI scores were the highest in the group 
of patients treated with standard therapeutic modal-
ities (11.05±9.550).
The factor analysis showed no statistically sig-
nificant  difference  between  the  values  of  PASI 
scores among the tested groups of patients (p = 
0.145). The third measurement (in the sixth week 
of  treatment)  showed  that  the  group  of  patients 
treated with balneotherapy had the lowest mean 
values of PASI score (2.85 ± 2.556); whereas the 
patients  treated  with  standard  therapy  had  the 
highest value (5.68 ± 4.423).
There was no statistically significant difference 
in PASI scores between different groups of all pa-
tients (p = 0.54). The use of Robust test showed a 
statistically significant difference in the values of 
PASI score (in sixth week) between different groups 
of patients (p = 0.037). In order to determine which 
groups of patients differed significantly among 
themselves, Post-hoc tests (Tukey post-hoc test) were 
used. These statistical tests showed that there were 
statistically significant differences in the values of 
PASI scores measured in the sixth week of treatment 
among the patients treated with standard therapeutic 
modalities and balneotherapy (p = 0.043). However, 
Graph 1. Subjects by gender and age
Grafikon 1. Ispitanici po polu i starosti
Graph 2. Distribution of patients by diagnosed form 
of psoriasis
Grafikon 2. Distribucija pacijenata prema dijagnosti-
kovanom obliku psorijaze
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there was no difference between the group treated 
with combination therapy and the one treated with 
standard therapy (p = 0.443), and the group treated 
with combination therapy and balneotherapy (p = 
0.577). The results of Friedman’s test showed that 
there  were  statistically  significant  differences  be-
tween the values of PASI scores determined in the 
first, third and sixth week of treatment in all patients 
(60 patients) (p = 0.000). The values of PASI score in 
the sixth week of measurements were statistically 
significantly lower than the values of PASI score in 
the  first  week  (Wilcoxon’s  test:  Z  =  -6.031,  p  = 
0.000) and the values of PASI score in the third week 
(Wilcoxon’s test: Z = - 5.626, p = 0.000). Also, the 
values of PASI scores determined in the third week 
of  treatment  were  statistically  significantly  lower 
than the values in the first week (Wilcoxon’s test: Z 
= - 6.031 p = 0.000). The value of PASI score during 
the study period of six weeks in all treated patients 
statistically significantly decreased because of ap-
plied therapeutic modalities (Graph 3).
The average values of CRP are shown in Table 
2. The difference between the average value of CRP 
at the beginning and at the end of treatment was not 
statistically significant in any of the groups, but after 
the end of treatment, there was a decrease in the val-
ue of CRP as a result of therapy. The factor analysis 
of the average value of CRP in the first and second 
measurements showed that there was no statistically 
significant difference in CRP levels among the study 
groups (p = 0.326 and p = 0.605).
The therapy applied for six weeks led to an in-
crease in the value of iron in most patients, no matter 
whether the patient had had a reduced iron value     or 
the values     of iron had been within the reference val-
ues. The average value of iron in all patients in the 
first week of treatment was 18.95±7,834 µmol/L and 
in the sixth week 19.10±5.996 µmol/L. The recorded 
increase in the value of iron in the sixth week by 0.15 
µmol/L was not statistically significant (Table 2). 
The factor analysis of the average values of TIBC in 
relation to therapeutic modality showed that there 
was  no  statistically  significant  difference  in  both 
measurements among all tested patients treated with 
different modalities (TIBC in the first week of p = 
0.062, and in the sixth week of p = 0.352). The factor 
analysis of the average values of UIBC in relation to 
therapeutic modality showed that there was no sta-
tistically  significant  difference  in  both  measure-
ments among all tested patients treated with differ-
ent therapeutic modalities (UIBC in the first week 
of p = 0.659, UIBC in the sixth week of p = 0.698). 
The average value of ferritin in all patients was 
80.56 ng/mL. The highest value was in the pa-
tients treated with balneotherapy (90.17 ng/mL), 
and the lowest in the patients treated with stand-
ard therapeutic modalities (71.91 ng/mL). Differ-
ences in ferritin values were not statistically sig-
nificant (p = 0.829).
Uric acid levels in the psoriasis patients treated 
with  different  therapeutic  modalities  are  shown  in 
Table 2. The factor analysis did not establish that 
these differences of mean values uric acid were sta-
tistically significant in the first and sixth week among 
different groups of patients (p = 0.929 and p = 0.599).
The ASTO values were tested by Kruskal-Wal-
lis test, and the results showed that there were no 
statistically significant differences in the values of 
ASTO titer in the first week (H = 3.082, p = 0.214) 
and at the end of the sixth week (H = 2.525, p = 
0.283) among different groups of patients.
Rf-values of the test latex and Waaler-Rose test 
were determined in patients during the first and at 
the end of the sixth week in the patients treated 
with different therapeutic modalities. In our study 
there  were  only  few  respondents  with  positive 
rheumatoid factor value.
Graph 3. PASI score determined in the first, third and 
sixth week of treatment with different therapeutic met-
hods
Grafikon 3. PASI skor određen u prvoj, trećoj i šestoj 
nedelji lečenja različitim terapeutskim metodama 
PASI – indeks proširenosti i težine psorijaze
Table 1. Average PASI score determined in the first, third and sixth week of treatment with different therapeutic 
methods
Tabela 1. Prosečni PASI skor određen u prvoj, trećoj i šestoj nedelji lečenja različitim terapeutskim metodama
Average PASI score±SD
PASI Prosečni skor
Standard therapy
Standardna terapija
Balneotherapy
Balneoterapija
Combination therapy
Kombinovana terapija
First week/Prva nedelja 24.65±20.452 12.16±11.070 21.48±15.091
Third week/Treća nedeljna 11.05±9.550 6.36±6.410 10.60±7.528
Sixth week/Šesta nedelja 5.68±4.423 2.85±2.556 4.17±3.950
N (number of patient)/N (broj pacijenata) 26 19 15
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The success rate of psoriasis treatment is defined 
by the duration of remission. The analysis of the ob-
tained results showed that the remission lasted for 
1.77 ± 0.951 months on average in the group of pa-
tients treated with standard therapeutic modalities. In 
the patients treated with balneotherapy the remission 
lasted for 1.79 ± 0.918 months on average, whereas in 
the patients treated with combination therapy of re-
mission it lasted for 2.47 ± 0.743 months on average.
Discussion
The prevalence of psoriasis is the same in both 
sexes and in all socio-economic groups in society 
[2]. There were 62% of men and 38% of women in 
our study sample. The average age of the partici-
pants was 48.6 (the youngest respondent was  20 
and the oldest 83 years of age). The highest number 
of patients had stable, localized or generalized form 
of plaque psoriasis (51.7%), which is consistent with 
the literature data [9]. 
The PASI score is determined at the beginning, 
during and at the end of the treatment in order to 
evaluate the success of a particular treatment in pso-
riasis [13]. The greatest values     in the PASI score in 
the first week were found in the group of patients 
treated with standard therapy (24.65 ± 20.452) and 
the smallest group of patients treated with balneo-
therapy (12.16 ± 11.070). During the measuring of 
PASI score, the values in the sixth week of treatment 
showed that the patients treated with balneotherapy 
had the lowest average value of 2.85 ± 2.85, and the 
patients treated with standard therapy had the high-
est  value  (5.68  ±  4.423).  The  use  of  Robust  test 
showed a statistically significant difference in the 
values     of PASI score in the sixth week among differ-
ent groups of patients (p = 0.037). The comparative 
analyzes and the Tukey and least significant differ-
ence (LSD) tests showed that a statistically signifi-
cant difference occured in the values of PASI score 
in the group of patients treated with standard therapy 
and balneotherapy (p = 0.043 and p = 0.017). The 
differences between the combination therapy and the 
standard  therapy  were  not  statistically  significant, 
but the values     of both groups were significantly low-
er than in the baseline PASI score (p = 0.443 and p = 
0.226). In addition, the difference between the com-
bination therapy and balneotherapy was not statisti-
cally significant, but the values of PASI score in the 
combined  therapy  were  significantly  lower  com-
pared to the PASI score values at the beginning (p = 
0.319 and p = 0.577).
The results of our study indicate a positive effect 
of the combined treatment of psoriasis using standard 
therapy modalities and balneotherapy. The study on 
the treatment of chronic plaque psoriasis conducted 
in the Comano Spa in Italy in 2008 had also con-
firmed this result. There was a reduction of PASI 
score within two weeks after the implementation of 
combination therapy (photobalneotherapy) (p <0.001) 
[31]. Kazandijeva et al. note that climate therapy may 
be an alternative to conventional treatment of psoria-
sis [35]. 
CRP has been proposed as a marker for psoriasis 
severity assessment and monitoring of the disease 
because it is not based on visual assessment, unlike 
the PASI score [15]. The factor analysis of the aver-
age value of CRP in the first and sixth measurement 
showed that there was no statistically significant dif-
ference in CRP levels among the study groups (p = 
0.326 and p = 0.605). However, CRP remained slight-
ly elevated at the end of therapy. The reduction of the 
CRP value in all groups of patients was not statisti-
cally significant. The results are consistent with the 
results of Chodorowska et al. who found that the con-
centration of CRP remained elevated during remis-
sion, compared with healthy controls [16].
Hyperuricemia is frequently present in patients 
with psoriasis. This correlation was first observed 
by Eisen and Seegmiller in 1961. They found a cor-
relation between concentrations of uric acid in the 
serum and skin changes in 30-40% patients with 
psoriasis [18]. The patients treated with balneother-
apy  had  the  highest  average  values  (324.58  ± 
70.049), and the patients treated with combination 
therapy had the lowest average values of uric acid 
(294.44  ±  24.491).  The  application  of  combined 
therapy had the best effect in reducing serum uric 
Table 2. Average laboratory parameters by different therapeutic methods
Tabela 2. Prosečni laboratorijski parametric po različitim terapeutskim metodama
Laboratory parameters ±SD
Laboratorijski parametri±SD
Standard therapy
Standardna terapija
Balneotherapy
Balneoterapija
Combination therapy
Kombinovana terapija
C-reactive protein (mg/L) first week/prva nedelja 6,19±8,498 2,86±3,190 7,30±14,204
C-reactive protein (mg/L) sixth week/šesta nedelja 4,50±8,509 2,33±3,243 3,57±7,975
Iron/gvožđe
(µmol/L) first week/prva nedelja 17,90±8,021 20,76±2,019 18,45±6,120
Iron/gvožđe
(µmol/L) sixth week/šesta nedelja 18,56±5,292 19,70±1,706 19,29±5,421
Uric acid/mokraćna kiselina 
(µmol/L) first week/prva nedelja 339,61±97,647 344,26±75,990 332,07±26,210
Uric acid/mokraćna kiselina (µmol/L)
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acid. The average value of uric acid was 313.76 ± 
87.753 in all patients. These differences in mean 
values of serum uric acid were not statistically sig-
nificant in the first and sixth measurement in all 
patients (p = 0.929 and p = 0.599).
There were very few respondents in all thera-
peutic groups with ASTO positive values (> 200 
IU/ml).  ASTO  values      in  respondents  tested  by 
Kruskal-Wallis test showed that there was no statis-
tically significant difference in ASTO values in the 
first week (H = 3.082, p = 0.214) and at the end of 
the sixth week (H = 2.525, p = 0.283) among the 
different groups of patients. In order to determine 
the effect of different therapeutic modalities in the 
treatment  of  psoriasis,  we  followed  our  patients 
over a period of three months. The obtained results 
showed that there was no statistically significant 
difference in the duration of remission between the 
patients treated with the combination therapy and 
the patients treated with standard therapeutic mo-
dalities (p = 0.019) balneotherapy (p = 0.032).
It  can  be  noted  that  the  combination  therapy 
showed the best results in the treatment of psoria-
sis. The study of synchronous application of nar-
rowband UVB therapy and swimming in the Dead 
Sea in 60 ambulatory patients with psoriasis con-
ducted by Schiffner et al. showed good results of 
the combination therapy in psoriasis [36]. The study 
of Brockow et al, done in 160 adult patients with 
psoriasis and PASI score exceeding 10, who were 
treated with balneotherapy and UVB phototherapy, 
showed that the combination therapy was more ef-
fective than UVB therapy at the end of sixth week 
[37].  Bathing  in  geothermal  seawater  combined 
with NB-UVB therapy in psoriasis results in faster 
clinical  and  histological  improvement,  produces 
longer remission time and allows lower NB-UVB 
doses than UVB therapy alone [38].
Conclusion
It has been found that there is a statistically signifi-
cant difference in the duration of remission between 
the patients treated with the combination therapy and 
the patients treated with standard therapy or balneo-
therapy. The application of combined treatment shows 
the best results in the treatment of psoriasis. 
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